Md Yuzaiful Md Yusof
Md Yuzaiful Md Yusof
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds
Verified email at
TitleCited byYear
Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study
S De Vita, L Quartuccio, R Seror, S Salvin, P Ravaud, M Fabris, ...
Rheumatology 54 (12), 2249-2256, 2015
Targeting interleukin-6 in rheumatoid arthritis
MYM Yusof, P Emery
Drugs 73 (4), 341-356, 2013
The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review
AS Zayat, MY Md Yusof, RJ Wakefield, PG Conaghan, P Emery, EM Vital
Rheumatology 55 (3), 485-494, 2016
Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years’ experience at a single centre
MY Md Yusof, A Kabia, M Darby, G Lettieri, P Beirne, EM Vital, S Dass, ...
Rheumatology 56 (8), 1348-1357, 2017
Brief report: responses to rituximab suggest B cell–independent inflammation in cutaneous systemic lupus erythematosus
EM Vital, M Wittmann, S Edward, MY Md Yusof, H MacIver, CT Pease, ...
Arthritis & Rheumatology 67 (6), 1586-1591, 2015
A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features
YM El-Sherbiny, A Psarras, MYM Yusof, EMA Hensor, R Tooze, G Doody, ...
Scientific reports 8 (1), 1-11, 2018
Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus
MYM Yusof, D Shaw, YM El-Sherbiny, E Dunn, AC Rawstron, P Emery, ...
Annals of the rheumatic diseases 76 (11), 1829-1836, 2017
Primary myocardial disease in scleroderma—a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group
LA Bissell, M Yusof, M Yuzaiful, MH Buch
Rheumatology 56 (6), 882-895, 2017
Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status
MYM Yusof, A Psarras, YM El-Sherbiny, EMA Hensor, K Dutton, ...
Annals of the rheumatic diseases 77 (10), 1432-1439, 2018
Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions
MYM Yusof, EM Vital, S Das, S Dass, G Arumugakani, S Savic, ...
Annals of the rheumatic diseases 74 (9), 1734-1738, 2015
B cell therapies, approved and emerging: a review of infectious risk and prevention during use
MYM Yusof, EM Vital, MH Buch
Current rheumatology reports 17 (10), 65, 2015
Certolizumab pegol in rheumatoid arthritis: current update
M Fechtenbaum, MY Md Yusof, P Emery
Expert opinion on biological therapy 14 (6), 841-850, 2014
Biologics in systemic lupus erythematosus: current options and future perspectives
MYM Yusof, EM Vital, P Emery
British Journal of Hospital Medicine 75 (8), 440-447, 2014
B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress
MY Md Yusof, EMJ Vital, P Emery
Expert review of clinical immunology 9 (8), 761-772, 2013
Developing a self-reported comorbidity index to predict mortality of community-dwelling older adults
MYM Yusof, MA Horan, M Jones, L McInnes, PMA Rabbitt, N Pendleton
Archives of gerontology and geriatrics 50 (3), e63-e67, 2010
092. Efficacy and Safety of Rituximab in Rheumatoid Arthritis Patients with Concomitant Interstitial Lung Disease: 10-Year Experience at Single Centre
AR Kabia, MY Md Yusof, S Dass, EM Vital, P Beirne, P Emery
Rheumatology 54 (suppl_1), i86-i86, 2015
FRI0334 Safety of rituximab for remission maintenance in relapsing anca–associated vasculitis: repeat cycles on clinical relapse are associated with low rates of …
MYM Yusof, E Vital, S Dass, C Pease, M Martin, S Savic, M Buch, P Emery
Annals of the Rheumatic Diseases 72 (Suppl 3), A487-A487, 2013
Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus
AS Zayat, K Mahmoud, MY Md Yusof, S Mukherjee, MA D’Agostino, ...
Rheumatology 58 (2), 304-312, 2019
Rituximab-associated neutropaenia: Safety of retreatment rituximab therapy
JCF Ferreira, MYM Yusof, S Das, EM Vital, P Emery
Rheumatology 54, 74-74, 2015
Response to:‘Which B-cell subset should we target in lupus?’by Ferraccioli and Houssiau
G Arumugakani, EM Vital, MYM Yusof, DG McGonagle, P Emery
Annals of the rheumatic diseases 73 (4), e20-e20, 2014
The system can't perform the operation now. Try again later.
Articles 1–20